State Street’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-10,189
Closed -$11K 3915
2019
Q1
$11K Hold
10,189
﹤0.01% 3724
2018
Q4
$8K Sell
10,189
-21,258
-68% -$32K ﹤0.01% 3744
2018
Q3
$67K Buy
31,447
+1,752
+6% +$4.2K ﹤0.01% 3680
2018
Q2
$69K Buy
29,695
+5,854
+25% +$17K ﹤0.01% 3662
2018
Q1
$75K Buy
23,841
+3,174
+15% +$8.74K ﹤0.01% 3632
2017
Q4
$85K Buy
20,667
+7,567
+58% +$32.9K ﹤0.01% 3612
2017
Q3
$59K Hold
13,100
﹤0.01% 3656
2017
Q2
$44K Sell
13,100
-339,212
-96% -$1.41M ﹤0.01% 3604
2017
Q1
$3.25M Buy
352,312
+11,041
+3% +$97K ﹤0.01% 2909
2016
Q4
$2.63M Buy
341,271
+46,171
+16% +$424K ﹤0.01% 3001
2016
Q3
$3.37M Buy
295,100
+30,261
+11% +$352K ﹤0.01% 2769
2016
Q2
$3.26M Buy
264,839
+28,007
+12% +$340K ﹤0.01% 2845
2016
Q1
$2.4M Buy
236,832
+14,518
+7% +$170K ﹤0.01% 2934
2015
Q4
$5.01M Buy
222,314
+26,156
+13% +$536K ﹤0.01% 2535
2015
Q3
$3.26M Sell
196,158
-24,525
-11% -$492K ﹤0.01% 2750
2015
Q2
$4.92M Buy
220,683
+32,793
+17% +$809K ﹤0.01% 2625
2015
Q1
$4.84M Sell
187,890
-3,514
-2% -$89.1K ﹤0.01% 2580
2014
Q4
$4.16M Buy
191,404
+12,839
+7% +$263K ﹤0.01% 2660
2014
Q3
$3.38M Buy
178,565
+15,991
+10% +$321K ﹤0.01% 2752
2014
Q2
$3.79M Buy
162,574
+90,289
+125% +$2.23M ﹤0.01% 2739
2014
Q1
$2.43M Buy
72,285
+8,766
+14% +$295K ﹤0.01% 2972
2013
Q4
$1.88M Buy
63,519
+32,419
+104% +$594K ﹤0.01% 3098
2013
Q3
$477K Buy
+31,100
New +$576K ﹤0.01% 3354

State Street's OMED Position: Q2 2019 in Review

State Street sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 10,189 shares — an estimated $11K sold.

State Street first reported a position in OMED in Q3 2013 and held it in 23 quarters. The position peaked at $5.01M in Q4 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.

  • State Street reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • State Street sold 10,189 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $11K.
  • State Street first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 23 quarters.
  • State Street's OncoMed Pharmaceuticals, Inc. position peaked at $5.01M in Q4 2015.
  • 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.

Based on State Street's 13F filing for Q2 2019, filed 14 Aug 2019.